United States Osteoarthritis Drugs Market expected to grow at a CAGR of 8.8% during 2024-2031 | Top Companies - Bayer AG, OrthogenRx, Abbott Laboratories

"Global Osteoarthritis Drugs market to grow at a high CAGR of 8.8% during the forecast period 2024-2031." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/osteoarthritis-drugs-market?sp

United States: Recent Industry Developments

✅ In November 2025, Pfizer Inc. launched its new Tanezumab injectable therapy for moderate-to-severe osteoarthritis pain, offering targeted nerve growth factor inhibition to reduce joint discomfort. The therapy provides an alternative for patients unresponsive to conventional NSAIDs. It underscores Pfizer's commitment to innovative osteoarthritis treatments.

✅ In October 2025, Johnson & Johnson (Janssen Pharmaceuticals) introduced a sustained-release anti-inflammatory formulation for knee osteoarthritis, improving patient adherence and reducing dosing frequency. The therapy targets localized joint inflammation with fewer systemic side effects. It highlights J&J's focus on patient-centric osteoarthritis management.

✅ In September 2025, Eli Lilly expanded its clinical program for oral small-molecule inhibitors targeting cartilage degradation in osteoarthritis, aiming to slow disease progression. The studies include multicenter U.S. trials with biomarker-guided endpoints. It reflects Lilly's investment in disease-modifying osteoarthritis drugs.

✅ In August 2025, Regeneron Pharmaceuticals initiated Phase III trials for its monoclonal antibody therapy for osteoarthritis, focusing on pain reduction and functional improvement in large joint disease. The trials aim to demonstrate long-term efficacy and safety. It emphasizes Regeneron's leadership in biologic approaches to joint disorders.

Japan: Recent Industry Developments

✅ In November 2025, Taisho Pharmaceutical Co., Ltd. launched an oral NSAID with improved gastrointestinal safety for osteoarthritis patients in Japan, reducing the risk of stomach-related side effects. The product addresses unmet needs in long-term pain management. It demonstrates Japan's focus on safer pharmacological options for osteoarthritis.

✅ In October 2025, Daiichi Sankyo introduced a transdermal anti-inflammatory patch for knee osteoarthritis, enabling sustained pain relief with convenient local delivery. The product improves compliance and reduces systemic exposure. It reflects Daiichi Sankyo's innovation in patient-friendly osteoarthritis therapies.

✅ In September 2025, Kissei Pharmaceutical Co., Ltd. expanded its pipeline with a disease-modifying osteoarthritis drug (DMOAD) targeting cartilage regeneration, entering early clinical trials in Japan. The approach aims to slow disease progression and improve joint function. It highlights Japan's growing focus on regenerative therapies for osteoarthritis.

✅ In August 2025, Chugai Pharmaceutical Co., Ltd. initiated studies of a novel monoclonal antibody therapy for osteoarthritis pain management, exploring efficacy in combination with physical therapy regimens. The trials aim to optimize functional outcomes for patients. It underscores Japan's commitment to advanced biologic osteoarthritis treatments.

Osteoarthritis Drugs Market: Drivers

The osteoarthritis drugs market is experiencing steady growth as the global prevalence of osteoarthritis rises due to aging populations, obesity, and sedentary lifestyles. Osteoarthritis, a degenerative joint disease, requires long-term management using pharmacological treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, analgesics, and disease-modifying osteoarthritis drugs (DMOADs). Increasing patient awareness about joint health, early diagnosis, and pain management is driving adoption. Additionally, the rising burden of musculoskeletal disorders and the growing demand for non-invasive treatment options are further fueling market expansion. The focus on improving patient mobility, reducing inflammation, and enhancing quality of life is central to therapeutic development.

Technological advancements in drug formulation, including sustained-release, targeted delivery, and combination therapies, are enhancing treatment efficacy and patient compliance. Biologic therapies and regenerative medicine approaches, such as platelet-rich plasma (PRP) and stem cell-based treatments, are emerging as complementary options. Growing research initiatives and clinical trials for novel osteoarthritis therapies are expanding the drug pipeline. Moreover, increasing healthcare expenditure and supportive reimbursement policies in developed and emerging markets are improving patient access to treatment. With ongoing innovation, rising prevalence, and a focus on personalized therapy, the osteoarthritis drugs market is poised for sustained, growth-driven expansion in the coming years.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/osteoarthritis-drugs-market?sp

Osteoarthritis Drugs Market: Major Players

Bayer AG, OrthogenRx, Abbott Laboratories, Glaxosmithkline plc, Sanofi SA, Pfizer Inc, Zimmer Biomet, Anika Therapeutics Inc., Mylan (Viatris), Novartis AG.

Segment Covered in the Osteoarthritis Drugs Market:

By Route of Administration
Osteoarthritis drugs are administered through Oral, Parenteral, and Topical routes, depending on the severity and location of joint pain. Oral drugs dominate due to their ease of use and patient compliance, while parenteral options are preferred for advanced cases requiring faster relief.

By Drug Class
The market includes Non-steroidal Anti-inflammatory Drugs (NSAIDs), Analgesics, Corticosteroids, Hyaluronic Acid, and others. NSAIDs hold the largest share owing to their effectiveness in reducing pain and inflammation, whereas hyaluronic acid injections are gaining traction for long-term joint lubrication.

By Distribution Channel
Distribution occurs through Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Retail pharmacies lead the segment with strong accessibility and prescription-based sales, while online platforms are expanding rapidly due to convenience and home delivery options.

Research Process:

Both primary and secondary data sources have been used in the Osteoarthritis Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Osteoarthritis Drugs Market Research Industry:

➠ Who leads the Osteoarthritis Drugs industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Osteoarthritis Drugs market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Osteoarthritis Drugs market growth?
➠ What are the dominant sales and distribution strategies in the Osteoarthritis Drugs industry?

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=osteoarthritis-drugs-market
(Purchase 2 or more Repots and get 50% Discount)

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.